TSI or TRAb Test: What Is the Difference, and When Is Each Thyroid Antibody Test Ordered?

The results portal shows two lines that look like typos of each other. One reads “Thyrotropin Receptor Ab” with a number and a flag. The other, drawn at a different clinic last year, says “Thyroid Stimulating Immunoglobulin” with a completely different number and no flag at all. The person staring at the screen has a racing pulse, a new tremor in one hand, and an appointment in nine days. Which result is the real one?

Both are, in a sense. The TSI vs TRAb test question comes up constantly in endocrinology waiting rooms because the two tests measure closely related things by different routes, and laboratories are not consistent about which one they run or how they label it.

This explainer walks through what each test actually detects, why the numbers rarely line up between laboratories, when a clinician reaches for one rather than the other, and what a positive or negative result changes about the conversation that follows.

How does a TSI vs TRAb test actually work?

Both begin the same way: a single tube of blood from a vein in the arm, usually without any need to fast. The difference lies in what the laboratory does next.

A short vocabulary first. TSH, or thyroid-stimulating hormone, is the pituitary’s signal that tells the thyroid how hard to work. The TSH receptor is the protein on the surface of thyroid cells that receives that signal. An autoantibody is an antibody the immune system has mistakenly aimed at the body’s own tissue. In Graves’ disease, autoantibodies aim at the TSH receptor.

A TRAb test (TSH receptor antibody) is a competitive binding immunoassay. The laboratory mixes the patient’s serum with purified TSH receptors and a labeled probe, either tagged TSH or a tagged reference antibody. If the patient’s antibodies are present, they occupy the receptors and push the probe off. The amount displaced is converted into a number. Crucially, this method reports any antibody that binds the receptor: stimulating, blocking, or neutral. Older reports called this a TBII test, for TSH-binding inhibitory immunoglobulin.

A TSI test (thyroid-stimulating immunoglobulin), in its classic form, is a bioassay. Living cells engineered to carry human TSH receptors are bathed in the patient’s serum. If stimulating antibodies are present, the cells respond as they would to TSH, producing a messenger molecule called cyclic AMP or a light signal that can be measured. This detects function, not just binding.

One wrinkle matters. Some newer automated tests are also labeled “TSI” but are bridge immunoassays engineered to bind mainly stimulating antibodies rather than living-cell tests. Same name, different chemistry, different numbers. MedlinePlus groups all of these under the umbrella of thyroid antibody testing, and which version arrives on a report depends almost entirely on the laboratory that processed the sample.

What is the TSH receptor, and why do antibodies against it matter so much?

Picture a thermostat. When thyroid hormone in the blood dips, the pituitary releases more TSH, the receptor on thyroid cells picks up the signal, and the gland makes more hormone. When hormone rises, TSH falls. The loop keeps free T4 (the active, unbound form of the main thyroid hormone) within a narrow band.

A stimulating TSH receptor antibody behaves like a key jammed in the lock. It switches the receptor on and stays there, ignoring the pituitary entirely. The thyroid produces hormone around the clock, the pituitary senses the excess and shuts off its own TSH, and the laboratory pattern that results is the signature of Graves’ disease: a TSH near zero alongside a high free T4. The National Institute of Diabetes and Digestive and Kidney Diseases describes Graves’ disease as the most common cause of hyperthyroidism in the United States, and this mechanism is the reason.

Blocking antibodies do the opposite. They wedge the lock shut, so even normal TSH cannot get through, and the gland underproduces. Some people carry both types, and the balance can shift over months or years. That shifting balance explains a puzzle clinicians occasionally see: a person who was overactive drifts toward underactive, or the reverse, without any treatment change.

Two further properties give these antibodies outsized importance. First, the TSH receptor is also expressed on cells behind the eye, which is one reason antibody levels track with thyroid eye disease, the inflammation and swelling of orbital tissue that can accompany Graves’. Second, these antibodies belong to the IgG class, the type that crosses the placenta, so a pregnant person’s antibodies can act on the developing baby’s thyroid. TPO antibodies, the ones associated with Hashimoto’s, do neither of these things in the same way.

TSI vs TRAb test at a glance: a comparison table

The table below sets the two side by side. Read it with one caution: the labels on a laboratory report tell you the intended target, not necessarily the exact method, and methods drive the numbers.

Feature	TRAb (TSH receptor antibody)	TSI (thyroid-stimulating immunoglobulin)
What it detects	Any antibody that binds the TSH receptor: stimulating, blocking or neutral	Antibodies that stimulate the receptor (classic bioassay) or are selected for stimulating type (bridge assay)
Method	Competitive binding immunoassay	Cell-based bioassay, or a bridge immunoassay labeled TSI
Older names	TBII, TSH-binding inhibitory immunoglobulin	TSAb, thyroid-stimulating antibody; LATS historically
Typical use	Confirming Graves’ disease; pregnancy monitoring; pre-treatment baseline	Same purposes, plus separating stimulating from blocking activity when the picture is mixed
Reporting	Usually international units per liter against a WHO standard	Units vary: IU/L, percent of baseline, or a specimen-to-reference ratio
Main strength	Widely automated, fast, reproducible	Tells you what the antibody does, not just that it is there
Main limitation	Cannot distinguish stimulating from blocking	Less standardized; bioassays are slower and sensitive to handling

The practical takeaway is narrower than the table suggests. For a person with newly low TSH and high free T4, either test answers the main question, “is this Graves’ disease?”, because blocking antibodies rarely produce that hormone pattern. The TSI-specific question, “is this antibody stimulating or blocking?”, matters most when hormone levels and the antibody result seem to point in different directions, or in pregnancy, where the type of antibody predicts what a newborn might experience.

Who is usually offered a TSH receptor antibody test, and who is usually asked to wait?

These tests are not screening tools. They answer a specific question in someone whose thyroid function is already known to be abnormal or whose history makes the answer consequential.

People commonly offered a TRAb or TSI test include those with a new finding of low TSH and high free T4, particularly when the physical picture does not settle the cause on its own. Mayo Clinic notes that antibody testing may be used when the diagnosis of Graves’ disease is uncertain after examination and hormone tests. Others include:

• Pregnant people with current Graves’ disease or a past history of it, including those treated years earlier with radioactive iodine or surgery, because antibodies can persist after the gland is gone.
• People nearing the end of a course of antithyroid medicine, where the antibody level informs the discussion about stopping.
• People with eye symptoms suggestive of thyroid eye disease whose thyroid hormone levels are normal.
• Newborns of mothers with Graves’ disease, when the pediatric team judges the risk relevant.

People usually asked to wait, or not tested at all, include those with a normal TSH and no symptoms, since a positive antibody in that setting rarely changes anything and can cause needless worry. Someone with an unmistakable clinical picture may not need the test to begin care, though many clinicians still obtain a baseline. People with a diagnosis of Hashimoto’s and stable underactive thyroid are seldom tested unless hormone levels start behaving oddly. And repeating the test every few weeks is generally discouraged, because antibody levels change slowly and the noise between draws can outweigh any real trend.

The treating team weighs all of this against the individual’s history. A test that is essential for one person is unnecessary for the next, and the decision to order, defer or skip belongs to the clinician who knows the whole picture.

What is the most accurate test for thyroid problems?

The honest answer is that “thyroid problems” is three different questions, and each has its own best test.

Is the thyroid working normally? TSH is the most sensitive single test for that, which is why MedlinePlus and the NHS both describe it as the first blood test a clinician orders when thyroid disease is suspected. Because the pituitary reacts to tiny shifts in hormone, TSH moves before free T4 does. A TSH within range makes a significant thyroid function problem unlikely; an abnormal TSH prompts free T4 and sometimes T3.

Why is it overactive? Here antibody tests earn their place. A positive TRAb or TSI in someone with confirmed hyperthyroidism points strongly to Graves’ disease rather than a hot nodule (an overactive lump making hormone independently) or thyroiditis (inflammation that leaks stored hormone). The alternative is a radioactive iodine uptake scan, in which a small tracer dose shows how much iodine the gland absorbs and where. Graves’ shows diffuse high uptake; thyroiditis shows low uptake; a nodule shows a single hot spot. Mayo Clinic and Cleveland Clinic both list antibody testing and uptake imaging as complementary routes to the same answer, and clinicians often choose the blood test first because it avoids radiation and is easier in pregnancy, where uptake scans are avoided.

Is there something structural? Ultrasound answers that: nodule size, blood flow, texture. No antibody test does.

So no single test is “most accurate.” A person asking the question usually wants to know whether their diagnosis is solid, and the reassuring reality is that a low TSH, a high free T4 and a positive TSH receptor antibody together form one of the more clear-cut diagnostic combinations in endocrinology. The uncertainty tends to sit at the margins: mild disease, borderline antibodies, or results from mismatched laboratories.

Graves disease antibody test: how TSI and TRAb fit alongside TSH and free T4

Think of the workup as a funnel. The NHS pathway begins with a general practitioner ordering TSH and thyroid hormone levels; if those are abnormal, the person is referred and further tests follow. The antibody test sits near the bottom of the funnel, refining a diagnosis that hormone tests have already raised.

Reading the combinations helps make sense of a report:

• Low TSH, high free T4, positive TRAb or TSI: the classic Graves’ pattern. Most clinicians will treat this as confirmed.
• Low TSH, high free T4, negative antibodies: hyperthyroidism from another cause becomes more likely, such as a toxic nodule, thyroiditis, excess iodine exposure, or certain medicines. An uptake scan or ultrasound usually follows.
• Low TSH, normal free T4: subclinical hyperthyroidism, where the pituitary has noticed a change the hormone tests barely register. Antibody testing may or may not be added depending on symptoms and age.
• Normal TSH, positive antibodies: not a disease in itself. It may reflect early Graves’, treated Graves’, or thyroid eye disease without hormone excess.

One thing the antibody test does not do well is grade severity. A person can have a modest antibody number and a dramatically high free T4, or the reverse. Hormone levels describe how overactive the gland is right now; antibody levels describe the immune pressure driving it. The two correlate loosely across a population but poorly within one individual on one day.

Because the antibody result is interpreted against hormone levels drawn at the same time, it is worth asking that both be taken from the same blood draw where possible. A TRAb from one month and a free T4 from another leaves gaps that the treating team then has to fill with judgment rather than data.

Is TRAb positive in Hashimoto's? TRAb vs TPO antibodies explained

Usually not, but the overlap is larger than most explanations admit.

Hashimoto’s thyroiditis is the autoimmune condition that most often leads to an underactive thyroid. Its signature antibodies are different ones: TPO antibodies, which target thyroid peroxidase, the enzyme that assembles thyroid hormone, and thyroglobulin antibodies, which target the protein that stores it. Neither of these switches the TSH receptor on or off; they mark an immune attack that gradually damages the gland. MedlinePlus lists TPO and thyroglobulin antibodies as the tests most associated with Hashimoto’s, and TSH receptor antibodies as the ones most associated with Graves’ disease.

The overlap comes from two directions. A meaningful share of people with Graves’ disease also carry TPO antibodies, so a positive TPO on its own cannot separate the two conditions. And a smaller group of people with hypothyroidism carry blocking TSH receptor antibodies. A standard TRAb test, which detects binding rather than function, will read positive in those people even though their gland is underactive. A TSI bioassay, which measures stimulation, would usually read negative in the same sample. This is the clearest real-world example of why the two tests are not interchangeable.

So when a person with a Hashimoto’s diagnosis sees a positive TRAb, three explanations are plausible: blocking antibodies contributing to the underactivity, a mixed picture where the balance may shift, or an evolving diagnosis. None of these is an emergency, and none is resolved by the antibody number alone. The hormone levels and the trend over time carry more weight.

For the TRAb vs TPO antibodies question in plain terms: TPO tells you the immune system is targeting the thyroid; TRAb tells you it is targeting the receptor that controls output. The first is common in both conditions; the second is largely specific to Graves’ disease and its blocking-antibody cousin.

TRAb test positive meaning: what actually happens next?

A positive result is a piece of evidence, not a verdict, and its meaning depends entirely on the company it keeps.

In someone with low TSH and high free T4, a positive TRAb or TSI supports a diagnosis of Graves’ disease. The next conversation typically covers the three established routes to controlling hormone excess, which Mayo Clinic, Cleveland Clinic and the NHS all describe: antithyroid medicines from the thionamide class, which slow the gland’s hormone production; radioactive iodine, which shrinks the overactive tissue over months; and surgery to remove part or all of the gland. Beta blockers, which do not touch the thyroid but blunt the racing heart and tremor, are often part of early care. Which route suits which person depends on age, eye involvement, pregnancy plans, gland size and personal preference, and that choice sits with the treating team.

In someone with normal thyroid hormone levels, a positive result is more ambiguous. It may be an early signal, a leftover from treated disease, or the explanation for eye symptoms without hormone excess. Watchful monitoring is a common response.

A negative result does not fully exclude Graves’ disease. Mild or early cases can fall below the laboratory’s cutoff, and a clinician who still suspects Graves’ may repeat the test or move to an uptake scan.

The number itself carries some information. Across groups of patients, higher levels track with more active disease, more prominent eye involvement, and a higher chance of relapse when antithyroid medicine stops. Applied to one person, though, these are tendencies rather than predictions, and a single value should not be read as a forecast of how any individual’s disease will behave.

TSI test normal range: is there a level that confirms Graves disease, and why do laboratories disagree?

People searching for the number that “means Graves'” are looking for something that does not exist in a universal form. Every laboratory sets its own cutoff, and the same blood can produce different figures on different platforms.

TRAb results are usually reported in international units per liter, calibrated against a World Health Organization reference preparation. That sounds like it should standardize everything, but laboratories use different probes, different receptor preparations and different calibration curves, so a value that reads clearly positive on one system may sit at the margin on another. TSI bioassays are reported in still other ways: as a percentage of a baseline response, or as a specimen-to-reference ratio comparing the patient’s sample to a standard. Bridge immunoassays labeled TSI use their own units again.

Three rules follow from this:

• Interpret a result only against the reference range printed on the same report.
• Compare trends only when the same laboratory and the same method were used.
• Treat a value just above the cutoff as less certain than one far above it, and expect the clinician to weigh it accordingly.

Why the disagreement persists comes down to what each method is physically measuring. A binding assay counts antibodies that occupy the receptor. A bioassay counts how hard the cells respond. A person with a modest quantity of very potent antibodies can score low on one and high on the other. Neither is wrong; they are answering different questions.

For the person with two mismatched results from two clinics, the useful step is to ask each laboratory, or the ordering clinician, which method was used. Endocrinologists are accustomed to translating between them. What they cannot do is average the two numbers, because they are not measured on the same scale.

What the following days and weeks usually look like after the test

The blood draw itself is over in minutes, and the arm may carry a small bruise for a day or two. The waiting is the harder part.

Antibody results are rarely same-day. Automated TRAb tests are often processed alongside routine chemistry, while cell-based TSI bioassays travel to specialist laboratories and take longer. The ordering team can say what to expect for their particular setup.

If the result confirms Graves’ disease, the pattern of the next few months is fairly predictable in shape, even though the details are individual. Mayo Clinic describes a course of antithyroid medicine typically continuing for 12 to 18 months, with symptoms beginning to ease over several weeks to months as the gland’s stored hormone is used up and production slows. Early on, thyroid hormone levels are rechecked frequently so the prescribing clinician can adjust; later the intervals lengthen. Antibody levels are usually not repeated at each visit. A common approach is to recheck them toward the end of the planned course, when the result feeds into the conversation about whether to stop, continue, or consider a definitive option.

People choosing radioactive iodine or surgery follow different timelines, and both routes commonly lead to an underactive thyroid that then requires lifelong hormone replacement, which Cleveland Clinic and the NHS describe as an expected outcome rather than a complication.

In pregnancy, antibody testing is repeated at set points so the obstetric and endocrine teams can plan monitoring for the baby. After delivery, a newborn exposed to high maternal antibody levels may be watched for a period, since the antibodies clear from the infant’s blood over weeks.

Throughout, the person’s own job is straightforward: keep appointments, report new symptoms, and bring the earlier laboratory reports so that trends are read against the right baseline.

When TSI and TRAb matter most: pregnancy, thyroid eye disease and stopping treatment

Three situations turn these tests from confirmatory extras into central pieces of the plan.

Pregnancy. Because TSH receptor antibodies cross the placenta, a pregnant person with high levels can pass them to the fetus, where they may stimulate the baby’s thyroid. This risk exists even when the parent’s own thyroid has been removed or ablated, since the immune system keeps making the antibodies after the gland is gone. NIDDK notes that Graves’ disease during pregnancy requires close monitoring for this reason. A stimulating-specific TSI result is particularly informative here because blocking antibodies carry a different implication for the newborn. The obstetric team uses the level to decide how closely to monitor fetal heart rate and growth and whether the newborn needs thyroid testing.

Thyroid eye disease. The same receptor sits on cells behind the eye, and antibody levels tend to run higher in people with active eye involvement. Some people develop eye symptoms while their thyroid hormones are still normal; a positive antibody test in that setting can link the eye problem to Graves’ disease and bring an ophthalmologist into the team. Mayo Clinic notes that radioactive iodine may worsen eye disease in some people, which is one reason antibody levels and eye status are reviewed before that option is chosen.

Stopping antithyroid medicine. A person who has completed a course faces a decision: stop and watch, continue longer, or move to radioactive iodine or surgery. Antibody levels that have fallen to undetectable make sustained remission more plausible; levels that remain high make relapse more likely. Neither outcome is guaranteed either way, and the prescribing clinician weighs the antibody result alongside gland size, symptom history and the person’s own priorities. No one should stop or change a prescribed medicine on the strength of a laboratory number alone.

What people often get wrong about TSI and TRAb

Online forums are full of confident statements about these tests. Several deserve correction.

“TSI and TRAb are the same test with different names.” They target the same receptor but measure different things: binding versus stimulation. A person can be positive on one and negative on the other, most often when blocking antibodies are involved.

“A negative result rules out Graves’ disease.” It makes it less likely, not impossible. Mild or early disease can fall below the cutoff, and clinicians who still suspect Graves’ have other tools, including uptake imaging.

“A higher number means worse symptoms.” Symptom severity follows hormone levels, not antibody levels. Someone with a modest antibody value can feel far worse than someone with a high one.

“Once the thyroid is removed, the antibodies go away.” The immune system, not the gland, makes them. Levels often fall over time after treatment but can persist for years, which is why pregnancy monitoring continues after thyroidectomy or radioactive iodine.

“A TPO test can diagnose Graves’ disease.” TPO antibodies appear in both Graves’ and Hashimoto’s. Only the TSH receptor antibody tests distinguish them.

“Antibodies should be rechecked every month to see if treatment is working.” Treatment progress is followed with hormone levels. Antibodies change slowly and are usually rechecked at decision points, not routinely.

“Diet or supplements can bring the antibodies down.” No dietary approach has been shown in mainstream evidence to lower TSH receptor antibodies in a way that changes the disease course. Eating well supports general health, and iodine excess can worsen hyperthyroidism, but the antibody number is not a target anyone can move with food.

“Positive means lifelong disease.” Many people treated for Graves’ disease enter remission and their antibodies fall. A positive result at diagnosis describes the present, not a permanent state.

Questions to ask your care team about your TSI or TRAb result

Appointments are short and laboratory reports are dense. A few prepared questions can turn a confusing number into a shared understanding.

• Which test did you order, TRAb or TSI, and which method does this laboratory use? If I have an older result from elsewhere, can the two be compared?
• What is this laboratory’s cutoff, and how far above or below it am I? Does a borderline result change your confidence in the diagnosis?
• Were my TSH and free T4 drawn at the same time as the antibody test? If not, should they be repeated together?
• Given the antibody result, do I still need an uptake scan or ultrasound, or does the blood test settle the question?
• Do I have TPO antibodies as well, and does that change anything about how you expect my thyroid to behave over time?
• How does my antibody level feed into the choice between antithyroid medicine, radioactive iodine and surgery in my particular case?
• When do you plan to recheck the antibodies, and what result would change the plan?
• If I am pregnant or planning pregnancy, how will this level be used to monitor the baby, and should the test be repeated at particular stages?
• Do I have any signs of thyroid eye disease, and should an eye specialist be involved now or only if symptoms appear?
• Which symptoms should prompt me to contact you before my next scheduled visit?

Writing the answers down during the visit, or asking whether a summary can be added to the after-visit notes, saves the scramble of trying to remember them later. The point is not to second-guess the team but to leave with the same mental model they are working from, so that the next result, whichever laboratory produces it, lands in context rather than as another puzzle.

When to call your doctor: red-flag signs with Graves' disease or an abnormal thyroid antibody test

Most people with a positive TSH receptor antibody test will move through diagnosis and early treatment without an emergency. A few situations, though, warrant a same-day call or urgent care rather than waiting for the next appointment.

Seek emergency care for signs that hyperthyroidism has become severe, a state sometimes called thyroid storm: high fever, a very fast or irregular heartbeat, confusion or agitation, persistent vomiting or diarrhea, or fainting. Chest pain or severe shortness of breath at any stage needs the same urgency; an overactive thyroid can strain the heart, especially in older adults.

Call the treating team promptly, the same day, for any of the following:

• A sore throat with fever or mouth ulcers while taking antithyroid medicine. The NHS and Mayo Clinic both flag this because these medicines can, uncommonly, lower white blood cell counts, and the team may want a blood test before the next dose.
• Yellowing of the skin or eyes, dark urine, pale stools, or severe itching, which can signal a liver reaction to medicine.
• New or worsening eye symptoms: pain behind the eye, double vision, blurred or reduced vision, or an eye that will not close fully. Vision changes in thyroid eye disease are treated as urgent.
• In pregnancy, a persistently racing heartbeat, reduced fetal movement, or any new symptom the obstetric team has asked to hear about.
• In a newborn whose parent has Graves’ disease, poor feeding, irritability, a fast heartbeat, or poor weight gain.

Less urgent but still worth a message: a rash after starting medicine, symptoms that seem to be swinging from overactive toward underactive, or a laboratory result from another clinic that does not match the one on file.

None of this replaces the judgment of the people looking after you. When in doubt, the safer choice is the phone call, and the treating team would rather hear about a symptom that turns out to be nothing than miss one that mattered.

Frequently asked questions

What is the difference between a TSI and a TRAb test?

TRAb measures any antibody that binds the TSH receptor, whether it stimulates, blocks, or does neither. TSI measures antibodies that stimulate the receptor, either through a living-cell bioassay or a bridge immunoassay selected for stimulating types. Both point to Graves’ disease when positive alongside high thyroid hormone levels, but they use different methods and units, and their numbers cannot be compared directly.

What is the most accurate test for thyroid problems?

There is no single most accurate test, because thyroid problems are several questions. TSH is the most sensitive test for whether the gland is working normally. TRAb or TSI tests are the most specific for whether hyperthyroidism is caused by Graves’ disease. Ultrasound answers questions about nodules and structure. A low TSH, high free T4 and positive TSH receptor antibody together form a clear-cut diagnostic combination.

Is TRAb positive in Hashimoto's?

Usually not. Hashimoto’s is typically marked by TPO and thyroglobulin antibodies, and TRAb is most often negative. A minority of people with an underactive thyroid carry blocking TSH receptor antibodies, which a standard TRAb binding test will detect as positive even though the gland is underactive. A TSI bioassay, measuring stimulation, would usually be negative in the same person.

What level of TSI indicates Graves disease?

No universal number exists. Each laboratory sets its own cutoff, and TSI results may be reported in international units, as a percentage of baseline, or as a ratio depending on the method. A result should be read only against the reference range on that report, and always alongside TSH and free T4. Values just above the cutoff are less certain than values far above it.

What is the TRAb test positive meaning if my thyroid hormones are normal?

A positive TRAb with normal TSH and free T4 is not a diagnosis of active Graves’ disease. It may represent early disease that has not yet affected hormone levels, leftover antibodies after successful treatment, or the explanation for thyroid eye disease in someone whose gland is functioning normally. Clinicians commonly respond with monitoring rather than treatment, and the trend over time matters more than one value.

What if the TRAb test is positive and my TSH is low?

That combination, especially with a high free T4, strongly supports Graves’ disease. The next conversation usually covers the three established routes to controlling hormone excess: antithyroid medicine, radioactive iodine, and surgery, often with a beta blocker for symptoms early on. Which route fits depends on age, eye involvement, pregnancy plans and preference, and the decision rests with the treating team.

Is there a TSI test normal range I can compare across laboratories?

No. TSI methods differ enough that a value from one laboratory cannot be placed on another laboratory’s scale. Even TRAb tests calibrated to the same WHO standard produce somewhat different numbers on different platforms. Compare results only within the same laboratory and method. If you have results from two places, ask the ordering clinician which methods were used rather than trying to average them.

How is TRAb vs TPO antibodies used to tell Graves' from Hashimoto's?

TPO antibodies mark an autoimmune attack on the thyroid but appear in both conditions, so they cannot separate the two. TSH receptor antibodies, measured by TRAb or TSI, are largely specific to Graves’ disease and its blocking-antibody variant. In practice, clinicians read the antibody pattern together with TSH and free T4: overactive with TSH receptor antibodies suggests Graves’; underactive with TPO antibodies suggests Hashimoto’s.

Why do doctors order a Graves disease antibody test during pregnancy?

TSH receptor antibodies cross the placenta and can stimulate the developing baby’s thyroid. This applies even when the pregnant person’s thyroid was removed or ablated years earlier, because the immune system continues producing the antibodies. Measuring the level helps the obstetric and endocrine teams decide how closely to monitor the fetus and whether the newborn should be tested after birth.

Can a negative TRAb or TSI test rule out Graves' disease?

Not entirely. Mild or early Graves’ disease can produce antibody levels below the laboratory’s cutoff. When hormone tests show hyperthyroidism but antibodies are negative, other causes such as a toxic nodule or thyroiditis become more likely, and a radioactive iodine uptake scan or ultrasound typically follows. A clinician who still suspects Graves’ may also repeat the antibody test after an interval.

References

• MedlinePlus: Thyroid Antibodies
• NHS: Overactive thyroid (hyperthyroidism), Diagnosis
• Cleveland Clinic: Graves' Disease
• NIH NIDDK: Graves' Disease

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.